Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Syed Hamza Mufarrih
Deal Size : Inapplicable
Deal Type : Inapplicable
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
Details : Ferric Carboxymaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 08, 2025
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Syed Hamza Mufarrih
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients
Details : Iron Sucrose is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL
Details : Epinephrine Injection is indicated for emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from insect stings or bites, foods, drugs and other allergens.
Product Name : Epinephrine-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Disodium Hydrogen Phosphate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and "AP" Rated¹
Details : Sodium Phosphate is an approved small molecule, indicated as a source of phosphorous, for addition to large volume IV fluids, to prevent hypophosphatemia in patients with restricted or no oral intake.
Product Name : Sodium Phosphate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 02, 2024
Lead Product(s) : Disodium Hydrogen Phosphate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹
Details : Potassium Phosphates intravenous injection is a phosphorus replacement product indicated as a source of phosphorus, which is indicated for s to correct hypophosphatemia in adults and pediatric patients 12 years of age and older.
Product Name : Potassium Phosphate-Geneic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane, which is indicated in the treatment of primary systemic carnitine deficiency.
Product Name : Carnitor-Generic
Product Type : Amino Acid
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
Details : Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.
Product Name : Injectafer
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 26, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Injectafer (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with iron deficiency in adult patients with heart failure categorized.
Product Name : Injectafer
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 05, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paclitaxel protein-bound particles for injectable suspension is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. It is indicated for metastatic breast cance...
Product Name : Paclitaxel-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 02, 2023
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches Paclitaxel Protein-Bound Particles Injectable Suspension
Details : Paclitaxel protein-bound particles is a microtubule inhibitor indicated for metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer & metastatic pancreatic adenocarcinoma.
Product Name : Paclitaxel-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 02, 2023
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable